The survival benefit of sorafenib for unresectable liver cancer is approximately 3 months.

“they found the median survival of somebody who took seraphinib in medicare was around four months so in other words in the real world somebody taking the drug that improves survival lives 50 as long as the person taking sugar pill in the trial which just shows you that the grand canyon of difference between real world patients and clinical trial patients and in the real world they compared those people taking seraphinib who live four months to similar people who didn't take seraphinib and they also live four months”